VNDA (Vanda Pharmaceuticals) Stock Based Compensation: $9.1 Mil (TTM As of Mar. 2026)


VNDA Vanda Pharmaceuticals Inc VNDA
73 GF Score
Price $6.24
GF Value $5.54
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals Stock Based Compensation?

Vanda Pharmaceuticals VNDA -2.19% 73 Stock Based Compensation is $9.1 Mil as of Mar. 2026. GuruFocus rates VNDA with a GF Score™ of 73/100 and a GF Value™ of $5.54 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Vanda Pharmaceuticals's Stock Based Compensation for the three months ended in Mar. 2026 was $2.6 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $9.1 Mil.

Vanda Pharmaceuticals Stock Based Compensation Related Terms

Vanda Pharmaceuticals Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Vanda Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals Stock Based Compensation Chart

Vanda Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.37 16.28 14.04 12.43 9.47

Vanda Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.97 2.11 2.11 2.29 2.56
VNDA
73GF Score
Vanda Pharmaceuticals Inc VNDA
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vanda Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.1 Mil.

What does a Stock Based Compensation of $9.1 Mil mean?
Vanda Pharmaceuticals (VNDA) has a Stock Based Compensation of $9.1 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Vanda Pharmaceuticals and its competitors.
Is Vanda Pharmaceuticals' Stock Based Compensation too high?
Vanda Pharmaceuticals' current Stock Based Compensation is $9.1 Mil. Overall, Vanda Pharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' Stock Based Compensation compare to AVIR and OABI?
Vanda Pharmaceuticals' Stock Based Compensation of $9.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Vanda Pharmaceuticals and its competitors. Vanda Pharmaceuticals's current Stock Based Compensation is $9.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (VNDA) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.54, compared to a current price of $6.24 — trading 12.6% above its estimated fair value. The current Stock Based Compensation is $9.1 Mil. Vanda Pharmaceuticals' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Vanda Pharmaceuticals (VNDA), the current Stock Based Compensation is $9.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanda Pharmaceuticals (VNDA) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued. The current stock price of $6.24 is trading 12.6% above its estimated GF Value™ of $5.54. GuruFocus considers Vanda Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for VNDA:

  • Stock Based Compensation: $9.1 Mil
  • GF Value™: $5.54 vs. price of $6.24 (12.6% above fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the VNDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanda Pharmaceuticals Business Description

Other Exchanges 0LKB:UKVM4:Germany
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
73GF Score

Get the complete analysis for VNDA

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.24
Price
$5.54
GF Value